Side-by-side · Research reference
CardiogenvsPNC-27
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED5/46 cited
BAnimal-StrongHUMAN-REVIEWED18/41 cited
Cardiogen
Bioregulator · Cardiac
CardiacTissue target
Gene regulationMechanism
AnimalEvidence level
SQ · Variable protocols
PNC-27
p53-HDM-2 Peptide · Membrane-Targeting
In vitro / Pre-clinical only
01Mechanism of Action
Parameter
Cardiogen
PNC-27
Primary target
Cardiovascular cell gene expressionKhavinson 2022
Membrane-bound HDM-2 protein on cancer cell surfaceSarafraz-Yazdi 2022Krzesaj 2024
Pathway
Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasisKhavinson 2022
PNC-27 binds to membrane HDM-2 1-109 domain → transmembrane pore formation → rapid necrosis (poptosis)Pincus 2024Krzesaj 2024
Downstream effect
Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue
Immediate cell lysis and extrusion of intracellular contents; secondary mitochondrial membrane disruptionPincus 2024Krzesaj 2024
Feedback intact?
Presumed — peptide bioregulators act via gene regulation, not receptor agonism
N/A — cytotoxic mechanism, not signaling modulation
Origin
Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology
Chimeric design: p53 transactivating domain (12-26) fused to penetratin CPP sequenceSarafraz-Yazdi 2022
Antibody development
—
—
02Dosage Protocols
Parameter
Cardiogen
PNC-27
Standard dose
Variable — typically 10–20 mg per course
No standardised human protocol; animal-derived dosing.
—
Frequency
Intermittent courses — 10–20 days, repeated periodically
Khavinson-school bioregulators typically dosed as periodic interventions, not continuous.
—
Evidence basis
Animal models / mechanistic studies
No Phase 1+ human trials in PubMed.
Pre-clinical / In vitro
Route
Subcutaneous injection
—
Duration
10–20 day courses, repeated 2–4× per year
Russian geriatric protocols; unclear extrapolation to general populations.
—
Clinical status
—
Pre-clinical only — no human trials
In vitro and animal model data only.
In vitro concentrations
—
10–100 μM range
Effective concentrations in cell culture studies.
Shorter analogue
—
PNC-28 (28 AA variant)
Retains HDM-2 binding and cytotoxic activity.
03Metabolic / Fat Loss Evidence
Parameter
Cardiogen
PNC-27
Fat loss mechanism
—
None — cytotoxic anticancer agent
04Side Effects & Safety
Parameter
Cardiogen
PNC-27
Injection site reactions
Mild erythema, induration (presumed)
—
Systemic adverse events
No documented serious AEs in available literature
Very limited safety data; no rigorous pharmacovigilance.
—
Immunogenicity
Unknown — no antibody development studies published
—
Long-term safety
Unknown — no extended human trials indexed in PubMed
—
Human safety data
—
None available — no human trials conducted
Normal cell selectivity
—
In vitro: no cytotoxicity to normal cells (MCF-10-2A, peripheral blood mononuclear cells)Sarafraz-Yazdi 2010Thadi 2020
Normal cells express minimal membrane HDM-2.
Cancer cell specificity
—
Depends on membrane HDM-2 expression levels
Ovarian cancer lines with low membrane HDM-2 showed <30% necrosis.
Mitochondrial effects
—
Secondary mitochondrial membrane disruption in cancer cells
Absolute Contraindications
Cardiogen
- ·Active malignancy (theoretical peptide growth factor concern)
- ·Hypersensitivity to peptide components
PNC-27
- ·Human use — no clinical trials or safety data
Relative Contraindications
Cardiogen
- ·Acute cardiac events (no safety data in acute MI, unstable angina)
- ·Pregnancy / lactation (no reproductive toxicity data)
PNC-27
—05Administration Protocol
Parameter
Cardiogen
PNC-27
1. Reconstitution
Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.
PNC-27 has not been tested in human subjects. All data derive from in vitro cancer cell line studies and limited animal models. No approved clinical formulation, dosing protocol, or safety profile exists.Pincus 2024
2. Injection site
Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.
In vitro studies used 10–100 μM PNC-27 dissolved in cell culture medium. Peptide was added directly to cancer cell cultures (pancreatic, breast, colon, ovarian, leukemia lines) and incubated for 24–72 hours.
3. Timing
Variable — often evening injection. No established circadian preference.
Dual-labeled PNC-27 (green on N-terminus, red on C-terminus) demonstrated intact peptide binding to cancer cell membranes with combined yellow fluorescence at 30 minutes, persisting during cell lysis.Sookraj 2010
4. Storage
Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.
Cytotoxicity correlates directly with membrane HDM-2 expression levels. Blocking HDM-2's p53-binding domain (1-109) with monoclonal antibodies prevents PNC-27-induced necrosis.
5. Needle
27–30G insulin syringe, 45° angle for subcutaneous administration.
—
06Stack Synergy
Cardiogen
+ Thymalin
ModerateKhavinson-school multi-organ bioregulator approach: thymalin (thymic peptide) addresses immune senescence while cardiogen targets cardiac tissue. Combined use in geriatric populations demonstrated normalisation of cardiovascular, endocrine, and immune parameters with reduced mortality over 6–8 years of observation.
- Cardiogen
- 10–20 mg SQ · 10–20 day course
- Thymalin
- 10–30 mg IM · concurrent or sequential courses
- Frequency
- 2–4 courses per year
- Primary benefit
- Multi-system aging mitigation, cardiovascular and immune homeostasis
PNC-27
— no documented stacks